ArticleScientific reports2017
Myostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocyte recruitment.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Myostatin-dependent detrusor remodelling mediates contractility impairment in diabetic rats' bladder - a maximal elastance analysis.The Journal of physiology · 2026Article
- Vascular and musculoskeletal interactions: structure, function, and therapeutic strategies for sarcopenia and osteoporosis.MedScience · 2026Review
- Muscle mass as a resilence factor for endothelial health in obesity.npj metabolic health and disease · 2026Review
- Interplay between Skeletal Muscle Catabolism and Remodeling of Arteriovenous Fistula by Yes-Associated Protein 1 (YAP1) Signaling.Journal of the American Society of Nephrology : JASN · 2025Article
- Article
- Relationship Between Serum Myostatin and Endothelial Function in Non-Dialysis Patients with Chronic Kidney Disease.Diseases (Basel, Switzerland) · 2024Article
- Myostatin expression in lung cancer induces sarcopenia and promotes cancer progression.General thoracic and cardiovascular surgery · 2024Article
- Circulating CXCL9, monocyte percentage, albumin, and C-reactive protein as a potential, non-invasive, molecular signature of carotid artery disease in 65+ patients with multimorbidity: a pilot study in Age.It.Frontiers in endocrinology · 2024Article
- Characterization of TFIIE-regulated genes by transcriptome analysis.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Combined Transcriptome and Metabolome Analysis of Smooth Muscle of Myostatin Knockout Cattle.International journal of molecular sciences · 2023Article
- Article
- Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.Scientific reports · 2022Article
- An Antisense Oligonucleotide against a Splicing Enhancer Sequence within Exon 1 of theInternational journal of molecular sciences · 2022Article
- A Collagen Hydrolysate Containing Tripeptides Ameliorates Sarcopenia in Middle-Aged Mice.Molecules (Basel, Switzerland) · 2022Article
- Renal Ischemia/Reperfusion Early Induces Myostatin and PCSK9 Expression in Rat Kidneys and HK-2 Cells.International journal of molecular sciences · 2021Article
- Review
- Myostatin/Appendicular Skeletal Muscle Mass (ASM) Ratio, Not Myostatin, Is Associated with Low Handgrip Strength in Community-Dwelling Older Women.International journal of environmental research and public health · 2021Article
- Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling.Frontiers in medicine · 2021Review
- Myostatin: The Missing Link between Sarcopenia and Cardiovascular Disease in Chronic Kidney Disease?Journal of atherosclerosis and thrombosis · 2020Article
- Myostatin in the Arterial Wall of Patients with End-Stage Renal Disease.Journal of atherosclerosis and thrombosis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myostatin (Mstn) is a skeletal muscle growth inhibitor involved in metabolic disorders and heart fibrosis. In this study we sought to verify whether Mstn is also operative in atherosclerosis of abdominal aorta. In human specimens, Mstn expression was almost absent in normal vessels, became detectable in the media of non-progressive lesions and increased with the severity of the damage. In progressive atherosclerotic lesions, Mstn was present in the media, neointima, plaque shoulder and in infiltrating macrophages. Mstn co-localized with α-smooth muscle actin (α-SMA) staining and with some CD45+ cells, indicating Mstn expression in VSMCs and bloodstream-derived leukocytes. In vitro, Mstn was tested in VSMCs and monocytes. In A7r5 VSMCs, Mstn downregulated proliferation and Smoothelin mRNA, induced cytoskeletal rearrangement, increased migratory rate and MCP-1/CCR2 expression. In monocytes (THP-1 cells and human monocytes), Mstn acted as a chemoattractant and increased the MCP-1-dependent chemotaxis, F-actin, α-SMA, MCP-1 and CCR2 expression; in turn, MCP-1 increased Mstn mRNA. Mstn induced JNK phosphorylation both in VSMCs and monocytes. Our results indicate that Mstn is overexpressed in abdominal aortic wall deterioration, affects VSMCs and monocyte biology and sustains a chronic inflammatory milieu. These findings propose to consider Mstn as a new playmaker in atherosclerosis progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.